Yes, however... [Two-Stage / GS Designs]

posted by jatkins_5 – Philippines, 2014-11-01 00:20 (3887 d 00:29 ago) – Posting: # 13816
Views: 8,698

Hi ElMaestro,

❝ Yes, I would assume you can actually do that across some of the EU agencies.


Thanks, thats good to know..

❝ But how could you ever be in a situation where you'd wish to study a third product descriptively in a form of BE trial?


We'd actually want to compare C's pk data with A, in a non statistical way, for future marketing purposes.


Not sure I get everything here, and if you are asked how this approach influences the type I error do you have a good answer prepared?

I think it's time we review our stats for this. I haven't got a prepared answer, really. Perhaps a simulation might work?

Thank you very much for your valuable reply!

Jerry

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,674 registered users;
18 visitors (0 registered, 18 guests [including 11 identified bots]).
Forum time: 01:50 CEST (Europe/Vienna)

Medical researches can be divided into two sorts:
those who think that meta is better and those
who believe that pooling is fooling.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5